Sage Journals: Discover world-class research

Abstract

To determine risk factors of accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE), 72 patients with inactive disease and 36 ageand sex-matched controls were included. The intima-media thickness (IMT) of the common carotid artery was determined by ultrasound. Traditional risk factors and disease-related factors were recorded. Cardiovascular risk was estimated using SCORE (systematic coronary risk evaluation). Markers of inflammation, endothelial activation and vascular remodelling (matrix metalloproteinases (MMP-3, MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1)) were determined.

IMT was increased in patients (0.67 mm 0.13 versus 0.61 mm 0.11,P 0.05). Prevalence of hypertension (33% versus 6%,P 0.001), SCORE (2.2 (1.7–4.2) versus 1.7 (1.3–2.1),P 0.001), as well as parameters of inflammation (CRP 1.8 (0.6–5.8) mg/L versus 0.6 (0.2–1.0) mg/L,P 0.001) and endothelial activation (VCAM-1 505 (389–683) ng/mL versus 374 (322–427) ng/mL,P 0.001) and von Willebrand factor (138 (59–208)% versus 48 (24–92)%,P 0.001), were increased in patients. Vascular remodelling was altered: MMP-3 and TIMP-1 were increased (18 (10–29) ng/mL versus 8 (5–11) ng/mL,P 0.001, and 275 (216–352) ng/mL versus 230 (197–268) ng/mL,P 0.001, respectively), and MMP-9 was decreased in SLE (266 (147–412) ng/mL versus 348 (226–530) ng/mL, P 0.05).

Univariate analyses revealed that in patients IMT was associated with age, systolic blood pressure, SCORE and disease duration. In multivariate analysis, age and SCORE were independent predictors of IMT.

In conclusion, SLE patients have an increased IMT, which is associated with traditional risk factors. Non-traditional risk factors, such as endothelial activation, altered vascular remodelling and disease duration, might play an additional role.

Keywords

atherosclerosis risk factors systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Urowitz MB , Bookman AA , Koehler BE , Gordon DA , Smythe HA , Ogryzlo MA . The bimodal mortality pattern of systemic lupus erythematosus . Am J Med 1976; 60: 221–225 .

Esdaile JM , Abrahamowicz M , Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum 2001; 44: 2331–2337 .

Jimenez S , Garcia-Criado MA , Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome . Rheumatology (Oxford) 2005; 44: 756–761 .

Selzer F , Sutton-Tyrrell K , Fitzgerald SG et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus . Arthritis Rheum 2004; 50: 151–159 .

Manzi S , Selzer F , Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthritis Rheum 1999; 42: 51–60 .

Bruce IN , Urowitz MB , Gladman DD , Ibanez D , Steiner G . Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study . Arthritis Rheum 2003; 48: 3159–3167 .

Svenungsson E , Jensen-Urstad K , Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus . Circulation 2001; 104: 1887–1893 .

Doria A , Shoenfeld Y , Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus . Ann Rheum Dis 2003; 62: 1071–1077 .

Roman MJ , Shanker BA , Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003; 349: 2399–2406 .

10.

Vlachoyiannopoulos PG , Kanellopoulos PG , Ioannidis JP , Tektonidou MG , Mastorakou I , Moutsopoulos HM . Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study . Rheumatology (Oxford) 2003; 42: 645–651 .

11.

Libby P , Ridker PM , Maseri A . Inflammation and atherosclerosis . Circulation 2002; 105: 1135–1143 .

12.

Williams RC Jr , Harmon ME , Burlingame R , Du Clos TW . Studies of serum C-reactive protein in systemic lupus erythematosus . J Rheumatol 2005; 32: 454–461 .

13.

Meroni PL , Raschi E , Testoni C , Borghi MO . Endothelial cell activation by antiphospholipid antibodies . Clin Immunol 2004; 112: 169–174 .

14.

Ho CY , Wong CK , Li EK , Tam LS , Lam CW . Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus . Rheumatology (Oxford) 2003; 42: 117–122 .

15.

Belmont HM , Buyon J , Giorno R , Abramson S . Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited . Arthritis Rheum 1994; 37: 376–383 .

16.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

17.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE . Arthritis Rheum 1992; 35: 630–640 .

18.

Brevetti G , Silvestro A , Schiano V , Chiariello M . Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index . Circulation 2003; 108: 2093–2098 .

19.

Conroy RM , Pyorala K , Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project . Eur Heart J 2003; 24: 987–1003 .

20.

Gladman D , Ginzler E , Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum 1996; 39: 363–369 .

21.

Montauban van Swijndregt AD , De Lange EE , De Groot E , Ackerstaff RG . An in vivo evaluation of the reproducibility of intima-media thickness measurements of the carotid artery segments using B-mode ultrasound . Ultrasound Med Biol 1999; 25: 323–330 .

22.

de Leeuw K , Sanders JS , Stegeman C , Smit A , Kallenberg CG , Bijl M . Accelerated atherosclerosis in patients with Wegener’s granulomatosis . Ann Rheum Dis 2005; 64: 753–759 .

23.

Howard G , Sharrett AR , Heiss G et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators . Stroke 1993; 24: 1297–1304 .

24.

Van Bortel LM , Vanmolkot FH , van der Heijden-Spek JJ , Bregu M , Staessen JA , Hoeks AP . Does B-mode common carotid artery intima-media thickness differ from M-model? Ultrasound Med Biol 2001; 27: 1333–1336 .

25.

Brouwer JL , Bijl M , Veeger NJ , Kluin-Nelemans HC , van der Meer J . The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus . Blood 2004; 104: 143–148 .

26.

Seth S , Goyal NK , Jagia P et al. Carotid intima-medial thickness as a marker of disease activity in Takayasu’s arteritis . Int J Cardiol 2005; 108: 385–390 .

27.

Alarcon GS , Friedman AW , Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture . Lupus 1999; 8: 197–209 .

28.

Poredos P . Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis . Vasc Med 2004; 9: 46–54 .

29.

Galis ZS , Khatri JJ . Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly . Circ Res 2002; 90: 251–262 .

30.

Nomoto K , Oguchi S , Watanabe I , Kushiro T , Kanmatsuse K . Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1 . J Cardiol 2003; 42: 201–206 .

31.

Zucker S , Mian N , Drews M et al. Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity . J Rheumatol 1999; 26: 78–80 .

32.

Faber-Elmann A , Sthoeger Z , Tcherniack A , Dayan M , Mozes E . Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus . Clin Exp Immunol 2002; 127: 393–398 .

Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus

Abstract

Keywords

Get full access to this article

References